Subscribe to Newsletter

Basic & Translational Research

Subspecialties Retina

What’s Old is New (I)

| Mark Hillen

Big data EMR mining (and some basic research) identifies a 50-year old drug that appears to protect against AMD development

Subspecialties Retina

Culture Club

| Michael Schubert

A new tissue culture model of the retinal pigment epithelium may allow researchers to better understand the impacts of new interventions on the adult human retina

Subspecialties Refractive

Benchmarking Femtosecond Lasers

What does analysis of the last five years of literature on femtosecond lasers tell us about the priorities of the field, and the major contributors to it?

Subspecialties Retina

The Gene Genie

Sitting down with... Anneke den Hollander, Professor, Department of Ophthalmology, Radboud University Medical Center, Nijmegen, the Netherlands

Subspecialties Basic & Translational Research

Blasting Retinoblastoma

Though highly successful, retinoblastoma radio- and chemotherapy increases the risk of secondary cancer. Is there an alternative?

Subspecialties Neuro-ophthalmology

I Can See a ‘Brainbow’

| Michael Schubert

New neuroscience reveals that the synaptic connections between the retinal ganglion cells and the visual cortex are not as simple as first thought

Subspecialties Retina

Two Paths to Better Vision

| Michael Schubert

Two research teams have developed very different ways of tackling retinitis pigmentosa, but both hold great promise

Subspecialties Neuro-ophthalmology

A Sidekick for Sight

| Michael Schubert

Object motion detector cell function relies on a unique interneuron and a special ‘sidekick’ recognition protein

Subspecialties Basic & Translational Research

AMD Clinical Trials

| Mark Hillen, Roisin McGuigan

AMD is the leading cause of blindness in developed countries, and the third-leading cause in developing countries.

Subspecialties Retina

Interleukin Forward to a Promising Future in AMD

| Mark Hillen

A novel signaling pathway that leads to choroidal neovascularization has been identified – with obvious therapeutic potential

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer element

This new disclaimer element is now part of all brands. It is editable on the start page and will be shown on all pages

Once confirmed we store a cookie to not show the disclaimer again.